$750,000 of ACADIA PHARMACEUTICALS lobbying was just disclosed, from Q3 of 2025, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"Implementation of the Inflation Reduction Act of 2022, Orphan Cures Act (HR 946, S 1862), Give Kids A Chance (HR 1262, S 932), Cameron's Law (HR 1414), Accelerating Kids Access to Care Act (HR 1509, S 752), Small Biotech Innovations Act (HR 3731, S 1930). Implementation of the Inflation Reduction Act of 2022, Issues related to protecting patient access to medicines in Medicare and Medicaid, Issues related to access to medicines for Parkinson's disease patients, Issues related to Antipsychotic use in Medicare, Orphan Cures Act (HR 946, S 1862), EPIC Act (HR 1492, S 832), One Big Beautiful Bill Act (HR 1), Accelerating Kids Access to Care Act (HR 1509, S 752). Cameron's Law (HR 1414), One Big Beautiful Bill Act (HR 1)."
You can find more data on corporate lobbying on Quiver Quantitative.
ACAD Insider Trading Activity
ACAD insiders have traded $ACAD stock on the open market 9 times in the past 6 months. Of those trades, 0 have been purchases and 9 have been sales.
Here’s a breakdown of recent trading of $ACAD stock by insiders over the last 6 months:
- MARK C. SCHNEYER (EVP, CHIEF FINANCIAL OFFICER) has made 0 purchases and 4 sales selling 30,996 shares for an estimated $737,822.
- LAURA BREGE sold 14,446 shares for an estimated $314,633
- JAMES KIHARA (PRINCIPAL ACCOUNTING OFFICER) has made 0 purchases and 3 sales selling 5,327 shares for an estimated $109,374.
- ELIZABETH A. GAROFALO sold 1,600 shares for an estimated $41,560
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
ACAD Hedge Fund Activity
We have seen 140 institutional investors add shares of ACAD stock to their portfolio, and 179 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CITADEL ADVISORS LLC added 2,718,036 shares (+922.4%) to their portfolio in Q2 2025, for an estimated $58,628,036
- ASSENAGON ASSET MANAGEMENT S.A. removed 1,683,979 shares (-98.4%) from their portfolio in Q3 2025, for an estimated $35,936,111
- MARSHALL WACE, LLP added 1,639,315 shares (+496.2%) to their portfolio in Q2 2025, for an estimated $35,360,024
- POINT72 ASSET MANAGEMENT, L.P. removed 1,475,305 shares (-31.7%) from their portfolio in Q2 2025, for an estimated $31,822,328
- JACOBS LEVY EQUITY MANAGEMENT, INC removed 1,216,248 shares (-61.5%) from their portfolio in Q2 2025, for an estimated $26,234,469
- PICTET ASSET MANAGEMENT HOLDING SA added 1,149,578 shares (+264.3%) to their portfolio in Q2 2025, for an estimated $24,796,397
- GOLDMAN SACHS GROUP INC removed 889,882 shares (-37.7%) from their portfolio in Q2 2025, for an estimated $19,194,754
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
ACAD Analyst Ratings
Wall Street analysts have issued reports on $ACAD in the last several months. We have seen 10 firms issue buy ratings on the stock, and 1 firms issue sell ratings.
Here are some recent analyst ratings:
- JP Morgan issued a "Overweight" rating on 09/29/2025
- TD Cowen issued a "Buy" rating on 09/11/2025
- UBS issued a "Buy" rating on 09/09/2025
- RBC Capital issued a "Outperform" rating on 08/07/2025
- JMP Securities issued a "Market Outperform" rating on 08/07/2025
- Goldman Sachs issued a "Sell" rating on 08/07/2025
- Needham issued a "Buy" rating on 06/26/2025
To track analyst ratings and price targets for ACAD, check out Quiver Quantitative's $ACAD forecast page.
ACAD Price Targets
Multiple analysts have issued price targets for $ACAD recently. We have seen 17 analysts offer price targets for $ACAD in the last 6 months, with a median target of $31.0.
Here are some recent targets:
- Tessa Romero from JP Morgan set a target price of $33.0 on 09/29/2025
- Ami Fadia from Needham set a target price of $28.0 on 09/24/2025
- Ritu Baral from TD Cowen set a target price of $39.0 on 09/11/2025
- Ashwani Verma from UBS set a target price of $39.0 on 09/09/2025
- Uy Ear from Mizuho set a target price of $24.0 on 08/07/2025
- Jason N. Butler from JMP Securities set a target price of $35.0 on 08/07/2025
- Salveen Richter from Goldman Sachs set a target price of $17.0 on 08/07/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
